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Abstract
Background: Mosquito-borne viruses (MBVs) and parasites (MBPs) are transmitted through hematophagous
arthropods-mosquitoes to homoiothermous vertebrates. This study aims at developing a detection method to
monitor the spread of mosquito-borne diseases to new areas and diagnose the infections caused by MBVs and
MBPs.
Methods: In this assay, an ultra-sensitive chemiluminescence (CL) detection method was developed and used to
simultaneously detect 19 common MBVs and MBPs. In vitro transcript RNA, virus-like particles (VLPs), and plasmids
were established as positive or limit of detection (LOD) reference materials.
Results: MBVs and MBPs could be genotyped with high sensitivity and specificity. The cut-off values of probes
were calculated. The absolute LODs of this strategy to detect serially diluted in vitro transcribed RNAs of MBVs and
serially diluted plasmids of MBPs were 102–103copies/μl and 101–102copies/μl, respectively. Further, the LOD of
detecting a strain of pre-quantified JEV was 101.8–100.8PFU/ml, fitted well in a linear regression model (coefficient of
determination = 0.9678).
Conclusions: Ultra-sensitive CL imaging DNA hybridization was developed and could simultaneously detect various
MBVs and MBPs. The method described here has the potential to provide considerable labor savings due to its
ability to screen for 19 mosquito-borne pathogens simultaneously.
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Background
Mosquito-borne viruses (MBVs) are transmitted from
hematophagous arthropod/mosquitoes to homoiother-
mous vertebrates. As competent hosts, arthropods can
support large virus inocula, and transmit them from an
infected donor to a recipient during blood-feeding.
Three major families in MBVs include the Togaviridae,
Flaviviridae, and Bunyaviridae [1]. The globally pan-
demic MBV species encompass dengue virus (DENV),
Japanese encephalitis virus (JEV), yellow fever virus
(YFV), West Nile virus (WNV) [2] and chikungunya
virus (CHIKV) [3]. In China, MBVs severely affect
people living in tropical regions and rural areas. There
are more than 70 identified flaviviruses, of which 35 can
affect humans [4]. Factors like global warming, increased
population mobility, and urbanization influence the epi-
demic scope of MBVs and sometimes even result in sud-
den outbreak [5]. In 1999, the outbreak of WNV in New
York resulted in mass-scale animal mortality [6]. In
2012, the outbreak of WNV in Texas resulted in 1,868
human infections (89 deaths) and an economic cost of
more than $47 million [7]. In 2010, the outbreak of
CHIKV in Guangdong province of China led to 173
cases of human infections [8]. From 2005 to 2006, more
than 1.3 million cases of CHIKV infections were re-
ported in India [9]. The infected cases of DENV re-
corded by the World Health Organization (WHO) were
approximately 0.9 million [10]. However, actual infected
cases worldwide are likely to be more than 390 million;
96 million infected patients show the clinical or sub-
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clinical symptoms of DENV infection [11]. Each year,
more than 20,000 casualties are reported due to severe
infections of DENV [12].
In addition, malaria parasites and lymphatic filariae,
borne by mosquitoes, are currently the most common
parasites in the world [13, 14]. Malaria and lymphatic fil-
ariasis have been considered as the world’s highest prior-
ity control and eradication parasitic diseases due to their
wide prevalence [15, 16]. In tropical regions, these two
parasites share the same propagation host and may also
co-infect humans [17]. Mosquito-borne parasites (MBPs)
infecting humans include Plasmodium vivax, Plasmo-
dium malariae, Plasmodium falciparum and Plasmo-
dium ovale. Malaria is rampant in Asia, Africa, and
Latin America, with half of the world’s population living
in malaria-risk areas. In 2006, 250 million people were
infected by malaria and approximately 1 million deaths
were reported, among which children (<5 years) and
pregnant women were most affected [18]. Mosquito-
borne lymphatic filariae include Wuchereria bancrofti,
Brugia malayi and Brugia timori. Approximately 1.3 bil-
lion people are living in the lymphatic filariasis-risk
areas. Following malaria, lymphatic filariasis is the sec-
ond most prevalent arthropod-borne disease worldwide,
which affects 128 million people each year in Asia, Af-
rica, Western Pacific, and parts of America [19].
The spread of the mosquito-borne pathogens from the
epidemic areas to new ones poses a serious threat to the
monitoring, prevention, and control of disease [20]. Effi-
cient prevention, control, and treatment of mosquito-
borne diseases rely on the rapid detection of the
mosquito-borne pathogens and accurate diagnosis. Cur-
rently, methods for detecting MBVs and MBPs are
mainly based on genetic assays, which include real-time
PCR [21–25], isothermal amplification [26], oligonucleo-
tide microarray [27] and sequencing [28]. However,
these methods were designed for detecting only certain
species of MBVs or MBPs. A method that can simultan-
eously detect common MBVs and MBPs has not yet
been reported. In this assay, a reliable and portable,
ultra-sensitive chemiluminescence (CL) imaging DNA
hybridization was developed and used to simultaneously
detect common MBVs and MBPs. In vitro transcript
RNA, virus-like particles, and plasmids were established
as positive or limit of detection (LOD) reference mate-
rials. The specificity and sensitivity of the method was
validated in cultivated MBVs, simulated mosquito sam-
ples, reference materials, and non-MBVs.
Methods
Specimen collection and processing
Cultivated MBVs strains were obtained from the In-
stitute of Microbiology Epidemiology of the Academy of
Military Medical Sciences and National Institute for
Viral Disease Control and Prevention, China CDC. Ly-
sates (TIANamp Virus RNA Kit, Tiangen Biotech Beijing
Co., Ltd.) were added to all the viral samples prior to ex-
periments. Total RNAs were extracted using TIANamp
Virus RNA Kit as described in the manufacturer’s proto-
col (Tiangen Biotech Beijing, China) and stored at -70 °
C until use. Uninfected Aedes vigilax were obtained
from the Institute of Microbiology Epidemiology of
Academy of Military Medical Sciences and stored at
-70 °C until use.
Primers and probes design and evaluation
In this assay, 12 MBVs and 7 MBPs were chosen for
detection: DENV1-4, JEV, YFV, WNV, St. Louis en-
cephalitis virus (SLEV), CHIKV, eastern equine en-
cephalitis virus (EEEV), western equine encephalitis
virus (WEEV), Venezuelan equine encephalitis virus
(VEEV), P. vivax, P. malariae, P. falciparum, P. ovale,
W. bancrofti, B. malayi and B. timori. Complete gen-
omic sequences of these MBVs, 18S rRNA gene se-
quences of malaria parasites, SspI repeat DNA
sequence of W. bancrofti, and Hhal repeat region se-
quences of B. malayi and B. timori were downloaded
from the GenBank database. The sequences were
aligned using AlignX (a component of the Vector
NTI Advance 10.3.0) to compare the homology be-
tween potential targets belong to the same genus.
Gene-specific primers (GSPs) were derived from pub-
lished literature or designed from conserved regions
using Primer Premier 5 (PREMIER Biosoft Inter-
national, Palo Alto, USA). Reverse primers used in
Multiplex RT-PCR or PCR were biotin-labelled at 5′
end to form a CL reaction. The capture probes,
which were used to capture the target DNA amplifi-
cation fragments, were designed by Oligo 7 (Molecu-
lar Biology Insights, Inc., Colorado Springs, USA).
Continuous homologous sequences of congeners were
excluded. A human-original sequence was used as
negative control probe. A repeat sequence of (T)12
with an amino-labeled 3′-end was connected to the
3′-end of all the probes to fix the repeat sequence
with the aldehyde-chip surface. A repeat sequence of
(T)20 with a biotin-labeled 5′-end and an amino-
labeled 3′-end served as a quality control (QC) probe.
All the primers and probes were confirmed by NCBI
BLAST and synthesized by Sangon Biotech Co., Ltd.
(Shanghai, China).
To evaluate the efficiency of primers, serially diluted
viral RNAs or plasmid DNAs were amplified by RT-PCR
or PCR and resolved by 2% agarose gel electrophoresis.
Furthermore, the most efficient pairs of primers were
biotin labeled in reverse primers, and RT-PCR or PCR
was used to evaluate the DNA hybridization efficiency of
the capture probes.
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Preparation of in vitro transcript RNA
To verify the LOD of this strategy and calibrate the con-
centration of virus-like particles (VLPs), in vitro tran-
scribed RNAs of these MBVs were prepared. First,
plasmids were constructed by cloning target gene frag-
ments to PGM-T vector as described in the manufac-
turer’s protocol (Tiangen Biotech Beijing Co., Ltd.).
Following digestion with FastDigest Sal I restriction
endonuclease (ThermoFisher, Waltham, USA), the plas-
mids were purified by agarose gel and retrieved. Subse-
quently, in vitro transcribed RNAs were prepared with
TranscriptAid T7 High Yield Transcription Kit (Ther-
moFisher), digested by deoxyribonuclease (DNase) I, and
purified by phenol-chloroform extraction method as de-
scribed in the manufacturer’s protocol (ThermoFisher).
Further, in vitro transcribed RNAs were purified and
digested by DNase I using RNeasy Mini Kit (QIAGEN,
Mississauga, Canada) as described in the manufacturer’s
protocol. The purified RNAs were mixed with 2 × RNA
Loading Dye Solution (ThermoFisher) and resolved by
2% agarose gel electrophoresis. Finally, in vitro tran-
scribed RNAs were quantified by UV spectrophotometry
and subject to serial dilutions at a magnitude of 10 and
stored at -70 °C until use.
Preparation of virus-like particles
The maturation protein gene and coat protein gene of
MS2 bacteriophage were amplified by MS2-BamH I and
MS2-Hind III primers (modified from reference litera-
ture) [29], and the sequence was as follows: MS2-BamH
I, 5′-AAC GGA TCC CAT GGC TAT CGC TGT AGG
TAG CC-3′, MS2-Hind III, 5′-CAT AAG CTT CTT
CGA CAT GGG TAA TCC TCA TGT T-3′. The bases
in italics represent endonuclease sites of BamH I and
Hind III. The PET-MS2 vector was constructed using
the MS2 amplified fragment and PET-28a (+) vector
(Novagen, Merck KGaA, Darmstadt, Germany) and li-
gated using T4 DNA ligase (New England BioLabs® Inc.,
Ipswich, USA) after digestion with restriction enzymes
(BamH I and Hind III, ThermoFisher), according to the
manufacturer’s protocol. The Hind III restriction enzyme
site and protection bases were added to the 5′ end of
MBVs’ GSPs (both forward and reverse), and target
genes of these mosquito-borne viruses were amplified
and digested by Hind III restriction enzyme. PET-MS2
vectors were also digested by Hind III and dephosphory-
lated by alkaline phosphatase (New England BioLabs®
Inc.). Target gene fragments of MBVs and PET-MS2 vec-
tors were ligated using T4 DNA ligase and cloned to
BL21 (DE3) competent cells (Tiangen Biotech Beijing
Co., Ltd.), according to the manufacturer’s instructions.
These bacterial plasmids were induced by isopropyl-1-
thio-β-galactopyranoside (IPTG) to express VLPs and
lysed by sonication. The VLPs were precipitated by
PEG8000 and purified by 15–45% (w/v) sucrose density
gradient ultracentrifugation at 32,000× rpm for 6 h/4 °C
(Beckman, MAL-80 ROTOR, Brea, USA). The aliquot
containing VLPs was dialyzed against PBS at 4 °C for
24 h to remove sucrose. The purified VLPs were used as
positive RNA references materials.
Multiplex asymmetric RT-PCR and PCR amplification
The GSPs of MBVs and MBPs were used in two multi-
plex asymmetric RT-PCR systems and one multiplex
asymmetric PCR system, respectively. For optimal ampli-
fication efficiency, orthogonal experiment was used to
optimize the concentration of the GSPs. Briefly, the con-
centration ratio of the forward and reverse primers were
set to 1:5. The high, medium, and low concentrations of
primers were set based on the results of preliminary ex-
periments. The selected primer concentrations were de-
termined by evaluation of the amplification efficiencies
of the target genes. Each RT-PCR was performed in a
25 μl reaction volume, containing 12.5 μl of 2× One Step
Buffer, 1.0 μl of PrimeScript One-step Enzyme Mix
(DRR055A, Takara Biotechnology (Dalian) Co., Ltd.,
Dalian, China), 5 μl of total RNA template, and specific
primer mix. RT-PCR system A amplified the target genes
of mosquito-borne flavivirus included DENV, JEV, YFV,
SLEV, and WNV. System A contained GSPs of DC10418
(0.2 μmol), JEV-3UTR-F2 (0.28 μmol), YFV-3UTR-F1
(0.4 μmol), WNV-3UTR-F2 (0.2 μmol), SLE-3UTR-F1
(0.1 μmol), and CDC10564 (2 μmol). RT-PCR system B
amplified the target genes of mosquito-borne alphavirus
included EEEV, WEEV, VEEV, and CHIKV. System B
contained GSPs of EEE-E1-F (0.4 μmol), EEE-E1-R
(2 μmol), CHIKV-F1 (0.2 μmol), CHIKV-R2 (1 μmol),
WEE-F (0.08 μmol), WEE-R (0.4 μmol), VEEV-cap-F3
(0.12 μmol), and VEEV-cap-R3 (0.6 μmol). PCR was per-
formed in a 25 μl reaction volume containing 2.5 μl of
10× EX Taq Buffer, 0.5 μl of TaKaRa Ex Taq HS (RR006,
Takara Biotechnology (Dalian) Co., Ltd.), 200 μmol of
each dNTP, 5 μl of total DNA template, and specific pri-
mer mix. PCR system amplified target genes of plasmo-
dium and lymphatic filariae. PCR system contained
GSPs of MAL-F1 (0.16 μmol), MAL-R1 (0.8 μmol), BM/
WBF (0.08 μmol), WBR (0.4 μM), MGB-HhaI-For
(0.16 μmol), and MGB-HhaI-Rev (0.8 μmol). Amplifica-
tions were performed on a Veriti 96-Well Thermal
Cycler PCR system (Applied Biosystems, Foster City,
USA). RT-PCR was performed under the following con-
ditions: 30 min at 50 °C; 2 min at 94 °C; 45 cycles of
20 s at 94 °C, 20 s at 55 °C, and 20 s at 72 °C; and a final
extension of 5 min at 72 °C. PCR was performed under
the following conditions: 2 min at 95 °C; 45 cycles of
20 s at 94 °C, 20 s at 55 °C, and 20 s at 72 °C; and a final
extension of 5 min at 72 °C.
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DNA Hybridization and signal detection
Captured probes of MBVs and MBPs (50 μmol) were
used to establish the MBVs and MBPs capture-chip, and
the spotting was repeated thrice in the vertical direction
on a aldehyde modified glass slide (Baio Technology
Shanghai Co., Ltd., Shanghai, China) surface with uni-
form proportional printing buffer (5% glycerol, 0.1% so-
dium dodecyl sulfate (SDS), 6× saline-sodium citrate
buffer (SSC), and 2% (wt/vol) Ficoll 400) as described in
previous studies [30]. The QC probe, used at 12.5 μmol
final concentration, was spotted and repeated six to
seven times in the horizontal direction to calibrate the
CL signal values. Each aldehyde slide was divided into
10 blocks (11 × 11 mm) by a waterproof film to detect
10 different samples.
After amplification, the two multiplex RT-PCR reac-
tion products, amplified using the same template, were
blended. After 5 min of denaturation at 95 °C, the 5 μl
of RT-PCR mixtures or PCR products were immediately
placed on ice for 5 min and mixed with 5 μl of DNA
hybridization buffer (8× SSC, 0.6% SDS, 10% formyla-
mine, and 10× Denhardt). DNA hybridization mixtures
(10 μl) were hybridized on the MBVs or MBPs
capture-chip for 1 h at 45 °C. The capture-chip was
washed for 30 s each with 1× SSC and 0.2% SDS,
0.2× SSC, and 0.1× SSC at room temperature. The
capture-chip was incubated with 15 μl of streptavidin-
horseradish peroxidase (Str-HRP, Sigma-Aldrich, St.
Louis, USA) for 25 min at 37 °C. Subsequently, the
capture-chip was washed with PBST (phosphate buffer,
0.05% Tween 20) 10 s at room temperature. Finally, 10 μl
of pre-mixed CL HRP substrate luminal solution and
H2O2 (Millipore Corporation, Boston, USA) were added
to the capture-chip and detected immediately with a
micro-light level imaging system (developed in-house,
patent number CN201330010609) (The working principle
of this CL imaging DNA hybridization method were
showed in Fig. 2c).
Determination of cut-off values of capture probes
In this assay, low background CL imaging and self-
programming software were employed as the imaging
method and the interpretation software was used to read
the grey values of the probes. The grey values recorded by
the software were set to be in the range of 0–256. The CL
signal values of probes =mean of signal values of probes -
signal values of background. The CL signal value was cali-
brated as follows: the calibrated CL signal value of a
probe =mean of CL signal value of the probe / mean of
CL signal value of QC probe (the same detection block) ×
100. The cut-off values of probes were calculated as fol-
lows: cut-off value of a probe = average signal values of to
detect other pathogens (except the pathogen detected by
this probe) + 3 × standard deviation. Probe signal was con-
sidered positive when the value was greater than the cut-
off value of the probe.
Specificity and sensitivity
Due to the lack of MBVs and MBPs samples, the specifi-
city of the strategy was evaluated only by 6 cultivated
MBVs strains and an inactivated JEV Vaccine (Table 1).
The other MBVs and MBPs were evaluated by artificial
VLPs, in vitro transcribed RNAs, or plasmids. Further, a
panel of non-MBVs, which include tick-borne encephal-
itis virus (TBEV), avian influenza A (H5N1), 2009 influ-
enza A (H1N1) (PH1N1), seasonal influenza A (H3N2),
seasonal influenza A (H1N1), Hepatitis B virus (HBV),
Hepatitis C virus (HCV), adenovirus AD2, AD3, AD40,
rubella virus, mumps virus, and respiratory syncytial vi-
ruses (RSV) HK6 and B, were also used to determine the
specificity of the strategy.
To evaluate the LOD of this strategy, in vitro tran-
scribed RNAs or plasmids were quantified using UV
spectrophotometer, and the copy numbers were calcu-
lated, serially diluted to 10-fold, and were detected. Puri-
fied VLPs were also diluted and detected to determine
Table 1 Actual virus samples used in this assay
No. Genus Virus Type Source
1 Flavivirus Dengue virus 2 Cultivated strain Institute of Microbiology Epidemiology of Academy of Military Medical
Sciences, China
2 Japanese encephalitis virus Cultivated strain National Institute for Viral Disease Control and Prevention, China CDC
3 Japanese encephalitis virus Inactivated vaccine
strain
JEV Vaccine (P3)
4 Yellow fever virus Cultivated strain Institute of Microbiology Epidemiology of the Academy of Military Medical
Sciences, China
5 Alphavirus Eastern equine encephalitis
virus
Cultivated strain Institute of Microbiology Epidemiology of the Academy of Military Medical
Sciences, China
6 Western equine encephalitis
virus
Cultivated strain Institute of Microbiology Epidemiology of the Academy of Military Medical
Sciences, China
7 Chikungunya virus Cultivated strain Institute of Microbiology Epidemiology of the Academy of Military Medical
Sciences, China
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the relative concentrations as compared to in vitro tran-
scribed RNA.
Simulated detection of mosquito samples
To test simulated mosquito samples, uninfected mos-
quito pools of 50 Aedes vigilax were spiked with 50 μl
106 copies/μl part of single or mixed VLPs or plasmids.
Then the spiked mosquito pools were homogenized in
500 μl diluent containing 20% fetal bovine serum in
phosphate-buffered saline using T10 basic ULTRA-
TURRAX® small dispersing instrument (IKA, Staufen,
Germany). The homogenized samples were centrifuged
for 5 min at 12,000× rpm. Supernatants were removed
to clean microfuge tubes. RNA or DNA was extracted
from the supernatant using TIANamp Virus RNA Kit
(Tiangen Biotech Beijing Co., Ltd.) or TIANamp
Genomic DNA Kit (Tiangen Biotech Beijing Co., Ltd.),
respectively, as described in the manufacturer’s protocol.
Subsequently, the extracted RNAs or DNAs were ampli-
fied by RT-PCR or PCR systems and detected by the CL
imaging DNA hybridization assay.
Results
Primers and probes design and evaluation
The amplification efficiency of 81 GSPs, obtained from
published literatures, and 82 GSPs designed for this assay
were precisely evaluated by serially diluted viral RNAs or
plasmid DNAs. Biotin-labeled reverse primers were used
for multiplex asymmetric RT-PCR or PCR to evaluate
DNA hybridization efficiency of 223 capture probes. Fi-
nally, 20 GSPs and 21 probes were chosen to amplify the
MBVs and MBPs targeted genes and capture the target
DNA amplification fragments (Tables 2 and 3).
Construction of in vitro transcribed RNAs and VLPs
Nine in vitro transcribed RNAs of MBVs were prepared
to determine the LOD of the MBVs detection assay and
calibrate the concentration of VLPs. After purification,
in vitro transcribed RNAs were verified by agarose gel
electrophoresis (Fig. 1a) and quantified by UV spe-
ctrophotometry. The copy numbers of these in vitro
transcribed RNAs were calculated as: copy numbers
(copies/μl) = RNA concentration (ng/μl) × Avogadro con-
stant × 10-9/ (RNA length × 340 g/mol) (Table 4). The in
vitro transcribed RNAs were serial diluted to 10-fold
and stored at -70 °C until use.
Twelve VLPs containing the amplified target RNAs
were also prepared as the positive RNA references of the
MBVs detection strategy. RNase A and DNase I diges-
tion on the prepared VLPs showed that the nucleic acid
bands between 1,000 and 2,000 bp tolerated both en-
zymes due to their packaging in the internal section of
Table 2 The sequences of GSPs for multiplex asymmetric RT-PCR and PCR amplification
Pathogen Primer Sequence (5′ to 3′) Location Referencea Primer source
Dengue virus DC10418 TTGAGTAAACYRTGCTGCCTGTAGCTC 10,392–10,481 GQ398257 [21]
JEV JEV-3UTR–F2 GGACTGGGTTAACAAATCTG 10,525–10,544 EF107523 Present study
YFV YEF-3UTR-F1 AAACTACGGATGGAGAACCG 10,489–10,508 U54798 Present study
WNV WNV-3UTR-F2 AAGTTGAGTAGACGGTGCTGC 10,533–10,553 EU249803 Present study
SLEV SLE-3UTR-F1 GGATGTCAGGTAAACGGTGCT 10,451–10,471 FJ753286 Present study
Flavivirus CDC10564b GGGTCTCCTCTAACCTCTAGTCCT 10,569–10,592 GQ398257 [21]
EEEV EEE-E1-F ACACTAAATTCACCCTAGTTCGAT 11,376–11,399 AY705241 [22]
EEE-1-Rb GTGTATAAAATTACTTAGGAGCAGCATTATG 11,492–11,522 AY705241
CHIKV CHIKV-F1 TGGATGAACATGGAAGTGAA 7,121–7,140 DQ443544 Present study
CHIKV-R2b GCTGTAGTGCGTACCTATTT 7,496–7,515 DQ443544 Present study
WEEV WEE-F AGGGATACCCCCGAAGGTT 8,220–8,238 AF214040 [23]
WEE-Rb GTGAATAGCACACGGGTGGTT 8,302–8,322 AF214040
VEEV VEEV-cap-F3 GGGCGGCGCATGAGAGAAGC 3–22 U34999 Present study
VEEV-cap-R3b GTGACCTGCTTGGCTTCTACCTC 119–141 U34999 Present study
Plasmodium MAL-F1 GGGAGTGAAGACGATCAGATACC 443–465 HQ283215 Present study
MAL-R1b CCGTGTTGAGTCAAATTAAGCC 668–689 HQ283215 Present study
W. bancrofti BM/WBF AGCGTGATGGCATCAAAGTAG 1–21 L20344 [24]
WBRb AGGTTATACCAAGCAAACAAAAA 110–132 L20344
B. malayi/ B. timori MGB-HhaI-For GCAATATACGACCAGCAC 254–271 M12691 [25]
MGB-HhaI-Revb ACATTAGACAAGGAAATTGGTT 140–161 M12691
aGenBank accession numbers
bThese primers were labeled by biotin to give off CL signals
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Fig. 1 Determination of in vitro transcribed RNAs and VLPs by agarose gel electrophoresis. a Agarose gel electrophoresis of in vitro transcribed
RNAs. The size of the in vitro transcribed RNAs were marked above each lane and compared with a RNA marker (Thermo Fisher). b RNase A and
DNase I digestion of VLPs. Lane 1: PET-MS2 (RNase A); Lane 2: PET-MS2 (DNase I); Lane 3: PET-MS2 (RNase A + DNase I); Lane 4: PET-MS2; Lane 5:
YFV VLP(RNase A); Lane 6: YFV VLP (DNase I); Lane 7: YFV VLP (RNase A + DNase I); Lane 8: YFV VLP; Lane 9: EEEV VLP (RNase A); Lane 10: EEEV VLP
(DNase I); Lane 11: EEEV VLP (RNase A + DNase I); Lane 12: EEEV VLP. The size of VLPs are compared to a DNA marker (TaKaRa). The nucleic acids
between 1,000–2,000 bp are resistant to both RNase A and DNase I due to their packaging in the internal section of the VLPs
Table 3 Capture probe sequences for DNA hybridization




DENV-1 DEN1-X10830 GCCCAACACCAGGGGAAG 10,520–10,537 FJ687426
DENV-2 DEN2-X10831 GCCCAAGGYGAGATGAAGCT 10,535–10,554 GQ398257
DENV-3 DEN3-X10829 GGCCCGAGCACTGAGGGAAGC 10,507–10,527 FJ898444
DENV-4 DEN4-X10714 CGTAATAATCCCTAGGGAGGCC 10,380–10,401 EF457906
JEV JEV-10726 CCCACGGCCCAAGCCTCGTCTAGGAT 10,703–10,728 EF107523
YFV YFV-10679 CCTCCGCTACCACCCTCCCAC 10,667–10,687 U54798
WNV WNV-10768 AACTTCAAAGCCCAATGTCAGACCACG 10,650–10,676 EU249803
SLEV SLE-10553 GTGCAAAGCCCCTCATTCCGACTCG 10,522–10,546 FJ753286
EEEV EEEV-11424 GTTCGATGTACTTCCGAGCTATGGTGACGGTGG 11,393–11,425 AY705241
CHIKV CHIKV-7427 ATGGCCACCTTTGCAAGCTC 7,421–7,440 DQ443544
WEEV WEEV-8304 TCGAATGTCACGTTCCCATGCGACAAAC 8,277–8,304 AF214040
VEEV VEEV-50 AAATGGAGAAAGTTCACGTTGACATCGAGG 42–71 U34999
Plasmodium MAL-1207d TTAGATTGCTTCCTTCAGTACCTTATGAGA 547–576 HQ283215
P. falciparum1 PF1-1187 CTTTCGAGGTGACTTTTAGA 532–551 HQ283215
P. falciparum2 PF2-1182 AGCATTTCTTAGGGAATGTTGATTTTATAT 573–602 HQ283222
P. vivax PV-1173 AGAGTTTTCTCTTCGGAGTTTA 525–546 HQ283223
P. malariae PM-1181 ATTCATATTAATGAGTGTTTCTTTTAGATAGCT 569–601 AF145336
P. ovale PO-1152 TGGATGAAAARTTTTTAAATAAGAAAATTCCTTTC 391–425 JX977167
W. bancrofti WB-53 AGTATGAATGGAATTTTTAGCAATTTTTTTG 52–82 L20344
B. malayi/ B. timori BM-113 ATAAGCTTTTTTTAGTAGTTTTGGCACTTAATT 184–216 M12691
Quality controle QC TTTTTTTTTTTTTTTTTTTT
Negative controlf NC CAGAGATACATTGACC 1,215–1,230 NM_001128925
aA repeat sequence of (T)12 with an amino-labeled 3′-end was conjugated to the 3′-end of all the capture probes
bGenBank accession numbers
cThis capture probe was used to detect all the DENVs
dThis capture probe was used to detect all the malarial parasites
eA repeat sequence of (T)20 with an amino-labeled 3′-end and biotin-labeled 5′-end were used to calibrate the CL signal values during DNA hybridization
fA human-original sequence was used as negative control
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VLPs (Fig. 1b). To determine whether the target RNAs
had been packaged in the internal regions, RNase A and
DNase I digested VLPs were serially diluted (10-fold),
total RNA was extracted, amplified by both multiplex
RT-PCR and PCR (both based on the GSPs of RT-PCR
system A or B), and detected by MBVs hybridization
capture-chip. The results showed that DNase I did not
completely digested the DNA templates from high con-
centration VLPs; the extractions from low-concentration
VLPs could only be detected by RT-PCR but not PCR
Fig. 2 Amplification of serially diluted VLPs by both RT-PCR and PCR. a The layout of the MBVs hybridization capture-chip. The probe P is the QC
probe. The probe NC is the negative control probe. b Amplifications of serially diluted VLPs by both RT-PCR and PCR (both based on the GSPs of RT-
PCR system A or B). The results showed that although DNase I did not completely digest DNA templates in high concentration VLPs, the extraction of
low-concentration VLPs were only detected by RT-PCR and not by PCR, demonstrating that DNA templates had been diluted to sufficiently. c Principle
of the CL imaging DNA hybridization method. Step 1 shows that capture probes are fixed to the aldehyde-chip surface. Step 2 shows that
the denatured RT-PCR products are hybridized on the capture-chip. Steps 3–5 show the principle of CL detection. Biotin is incorporated into reverse
strand in RT-PCR amplification. When HRP modified streptavidin is bound, CL signal becomes illuminant by the catalyzed substrates
Table 4 The copy numbers of in vitro transcribed RNAs quantified by UV spectrophotometer
Virus RNA concentration (ng/μl)a Length (nt)b Copy number (copies/μl) c Location Referenced
SLEV 61 680 2 × 1011 10,451–10,933 FJ753286
WNV 550 654 1 × 1012 10,521–10,977 EU249803
VEEV 275 339 1 × 1012 1–142 U34999
JEV 1810 560 5 × 1012 10,525–10,887 EF107523
YFV 1930 853 4 × 1012 10,109–10,764 U54798
EEEV 1290 344 6 × 1012 11,376–11,522 AY705241
CHIKV 1700 590 5 × 1012 7,123–7,515 DQ443544
WEEV 510 303 4 × 1012 8,217–8,322 AF214040
DENV2 275 395 1 × 1012 10,392–10,589 GQ398257
aRNA concentrations were quantified by UV spectrophotometer
bThe lengths of in vitro transcribed RNAs were calculated on the length of the inserted gene fragments plus the transcript length of digested PGM-T vector
cCopy numbers (copies/μl) = RNA concentration (ng/μl) × Avogadro constant × 10-9/ (RNA length × 340 g/mol)
dGenBank accession numbers
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(Fig. 2b), thereby demonstrating that the DNA templates
had been diluted to sufficiently low concentrations that
cannot be detected.
Determination of cut-off value of capture probes
In this assay, the cut-off values of a probe were calculated
as follows, cut-off = average signal value to detect other
pathogens (except the particular pathogen detected by this
probe) + 3 × standard deviation. The cut-off values of all
the probes are shown in Table 5.
Evaluation of specificity
The specificity of the strategy was evaluated using
cultivated MBVs strains, inactivated JEV vaccine strain,
artificial VLPs, in vitro transcribed RNAs, and plasmids.
The results showed that this assay genotyped MBVs
and MBPs with no cross-reactions between the sam-
ples and reference materials (Fig. 3a, b). The CL sig-
nal value (i.e. that had not been calibrated) of each
probe was shown in 3-D bar chart (Fig. 3c, d). Further-
more, a panel of non-MBVs did not yield any positive
results with this strategy, suggesting the method is indeed
highly specific (Additional file 1: Figure S1).
Determination of LOD
To determine the absolute LOD of this strategy, serially
diluted in vitro transcribed RNAs or plasmids, which
had been quantified by the copy numbers, served as the
reference materials. The absolute LODs for the MBVs
were 102 copies/μl except for WNV (103 copies/μl),
(Fig. 4a). The calibrated CL signal values of the in vitro
transcribed RNAs are described in a line chart (Fig. 4c).
Further, the absolute LODs for P. falciparum, P. ovale,
and P. malariae are 101 copies/μl; for the others, the
values are 102 copies/μl (Fig. 5a). The calibrated CL
values of these plasmid DNAs are also described in a
line chart (Fig. 5b)
A strain of JEV virus derived from National Institute
for Viral Disease Control and Prevention was also
employed as a reference material to determinate the
LOD of this strategy. The results showed that the LOD
for JEV was between 101.8 PFU/ml and 100.8 PFU/ml
(Fig. 4b). A linear regression model based the calibrated
CL signal values against the JEV concentrations shows
satisfactory fitness, with the coefficient of determination
being 0.9678 (Fig. 4d).
Simulated detection of mosquito samples
To test simulated mosquito samples, uninfected mosquito
pools of 50 Aedes vigilax were spiked with 106 copies/μl
of six single VLPs and plasmids or mixed VLPs and plas-
mids, followed by the CL imaging DNA hybridization
assay. The results showed that this assay could detect all
mimic samples of single MBVs, single MBPs, mixed
mosquito-borne flavivirus, mixed mosquito-borne alpha-
virus, and mixed MBPs (Fig. 6). Therefore, the proposed
assay can potentially test targeted MBVs and MBPs in ac-
tual mosquito samples.
Discussion
As a competent vector, arthropods can support the suffi-
ciently large inoculum of the virus and transmit the
MBVs from an infected donor to a recipient host during
blood-feeding. MBVs are also transmitted between male
and female mosquitoes or from a female to the offspring.
Furthermore, malaria and lymphatic filariasis, transmit-
ted by hematophagous arthropods, are still the most
prevalent mosquito-borne parasitic diseases in humans
[13, 14]. A continuous effort to monitor the MBVs is
critical to prevent sudden outbreaks [20]. Many gene-
based diagnostic methods have been used to detect
MBVs and MBPs. However, to the best of our know-
ledge, a portable, ultra-sensitive CL DNA hybridization
method to simultaneously detect common MBVs and
Table 5 Cut-off values of the capture probes






DEN-10731 0.50 0.67 2.51
DEN1-X10830 0.18 0.33 1.17
DEN2-X10831 0.85 1.55 5.50
DEN3-X10829 0.38 0.29 1.25
DEN4-X10714 0.15 0.22 0.81
JEV-10726 0.42 0.30 1.32
YFV-10679 1.90 3.80 13.30
WNV-10768 0.30 0.39 1.47
SLE-10553 0.19 0.14 0.61
EEEV-11424 0.29 0.43 1.58
WEEV-8304 0.64 0.85 3.19
VEEV-50 1.02 2.03 7.11
CHIKV-7427 0.23 0.37 1.34
MAL-1207 0.50 0.20 1.10
PF1-1187 0.10 0.14 0.52
PF2-1182 0.32 0.20 0.92
PV-1173 0.25 0.11 0.58
PM-1181 0.20 0.14 0.62
PO-1152 0.20 0.14 0.62
BM-113 0.43 0.42 1.69
WB-53 0.20 0.14 0.62
Abbreviation: SD standard deviation
aCut-off value of a probe (grey value) = average signal values of to detect
other pathogens (except the particular pathogen detected by this probe) +
3 × standard deviation. A probe signal was considered positive when the value
was greater than the cut-off value of a given probe
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MBPs has not been reported. Because of the lack of anti-
viral drugs [10, 31, 32], the use of vaccines has emerged
as an efficient strategy to control the spread of MBV dis-
eases [33]. At present, human vaccines for flavivirus and
alphavirus are available; however, these only include pre-
vention of YFV, JEV, and TBEV [34–38], while the hu-
man vaccines for the prevention of DENV, WNV,
CHIKV, SLEV, WEEV, EEEV and VEEV are still not ap-
proved for clinical trials [33, 39]. As a result, it has be-
come imperative to develop reliable methods for rapid
diagnosis, timely prevention, and efficient control of the
mosquito-borne diseases. Rapid diagnosis is not only the
indispensable method for controlling the infectious
diseases, but also the prerequisite for timely prevention
and efficient treatment. Infectious diseases are only able
to be effectively prevented and treated after rapid and
accurate diagnosis. Therefore, the spread of these infec-
tious diseases, for which the drugs are not yet estab-
lished, can be effectively reduced by controlling their
vectors and accurate monitoring. In this assay, we devel-
oped a portable, ultra-sensitive CL imaging DNA
hybridization method to detect various MBVs and MBPs
simultaneously. This method is based on horseradish
peroxidase catalyzing luminol-H2O2, and its perform-
ance proved to be highly sensitive and specific for the 12
MBVs and 7 MBPs that were included in the current
study. The traditional epidemic of these pathogens in-
volves many tropical and sub-tropical areas of Asia, Af-
rica, the Americans, Europe and the Pacific archipelago
[40–43]. Currently, there may not be a region in the
world where all 19 pathogens are present. So the inclu-
sion of the 19 pathogens in the current study appears
exceeding the needs of clinical detections. However, we
believe our study delivers a proof-of-concept study
where such a diagnostic assay may test for more patho-
gens and save significant labour and time when a patient
presents with symptoms of unknown etiology. Further-
more, given the fact that mosquito-borne diseases may
occur in non-endemic areas due to the uncertainties of
global human migration, for example, the first imported
cases of Zika virus in China and Europe [44, 45], a rapid
and ready-to-be-applied method will have significant
clinical implications. For point of care testing, a self-
powered portable CL CCD imager was developed. A
self-programming software was employed to interpret
the software readings and to study the grey values of the
probes. However, other commercial CL imagers based
on CCD imaging technology can also be used for CL im-
aging. Despite needing a CL imager, this CL imaging
method has lower cost and faster detection speed than
our previous visual method which was based on quantum
dot-catalyzed silver deposition [30].
Fig. 3 Specificity of the CL imaging DNA hybridization method. a and b Specificity of MBV and MBP detection, respectively. Cross-reaction is not
present in samples and reference materials. c CL signal value (not calibrated) of each probe for MBVs is shown in the 3-D bar chart. d CL signal
value (not calibrated) of each probe for the MBPs is shown in the 3-D bar chart. e Layout of the MBPs hybridization capture-chip. The probe P is
the QC probe. The probe NC is the negative control probe
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In the current study, due to the lack of pathogen nu-
cleic acid samples, we validated the specificity of our
method using the positive and negative references. The
absolute LOD, which was evaluated using serially diluted
in vitro transcribed RNAs and plasmids, was in the
range of 101–103copies/μl. A strain of JEV was also
employed as a reference material to determine the abso-
lute LOD. Results from the two repeat tests showed that
the absolute LOD for JEV was in the range of 100.8–
101.8PFU/ml, and fits well in a linear regression model,
demonstrating the feasibility of quantitative measure-
ment of viral load. The assay is rapid, portable, ultra-
sensitive, and high-throughput. The entire detection
time, spanning from sample extraction to result reading,
is between 6–8 h.
Since most of the targets in this assay are potent path-
ogens, we did not collect actual samples or all the nu-
cleic acids. Instead, 14 artificial target pathogen gene
sequences were constructed by overlap extension
method and cloned into plasmid vectors as well as those
target pathogens having nucleic acids samples (datas not
shown). Subsequently, RNAs of these target viruses were
in vitro transcribed from these plasmids. We observed
that DNA templates from the plasmids were not com-
pletely removed by DNase I digestion. Consequently,
RNeasy Mini Kit (QIAGEN), a purification method
based on spin column, was also employed to purify and
digest these in vitro transcribed RNAs on column. Al-
though residual DNA templates were not completely re-
moved from in vitro transcribed RNAs, they were
negligible after the concentrations of in vitro transcribed
RNAs were diluted to lower than 108 copies/μl due to
the twice DNase I digestion (dates not shown). Similar
issue was observed during the preparation of VLPs of
these target MBVs. However, to maintain the integ-
rity, the VLPs were not digested by DNase I on the
spin column. Consequently, the VLPs, as RNA posi-
tive reference materials, were also diluted to a suffi-
ciently low concentration to overcome the influence
of residual DNA templates as the concentration of
Fig. 4 Determination of LOD for MBVs detection. a Detection of serially diluted in vitro transcribed RNAs of MBVs. The results show that the absolute
LOD of this strategy to detect these MBVs is 102 copies/μl except for WNV (103 copies/μl). b Detection of a strain of JEV that had been accurately
quantified by the National Institute for Viral Disease Control and Prevention. The LOD to detect JEV is between 101.8–100.8 PFU/ml. c Calibrated CL
signals of diluted in vitro transcribed RNAs of MBVs. d Calibrated CL signal values are plotted as a linear function of JEV concentrations (inset). It fits
well in a linear regression model. The coefficient of determination is 0.9678. Data shown are representative of two independent experiments
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Fig. 6 Simulated detection of mosquito samples. Uninfected mosquito pools of 50 Aedes vigilax were spiked with 106 copies/μl of single VLPs
(DENV3, SLEV, WEEV, or VEEV), single plasmids (P. falciparum or B. malayi), mixed VLPs of mosquito-borne flavivirus (including DENV1-4, JEV, YFV,
SLEV, and WNV), mixed mosquito-borne alphavirus (including EEEV, WEEV, VEEV and CHIKV), or mixed plasmids of MBPs (including P. falciparum, P.
vivax, P. malariae, P. ovale, W. bancrofti and B. malayi). This assay could detect single MBVs and MBPs in the mimic samples, as well as mixed
mosquito-borne flavivirus, mixed mosquito-borne alphavirus, and mixed MBPs
Fig. 5 Determination of LOD for MBPs detection. a Absolute LODs for P. falciparum, P. ovale, and P. malariae is 101 copies/μl and 102 copies/μl for
the remaining species. b Calibrated CL values of plasmid DNAs are shown in a line chart
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residual DNAs were only 103–104-fold lower than
that of the RNAs within VLPs.
In the present assay, a uniform reverse primer located
in the 3′UTR region of flavivirus genome was employed
in the multiplex asymmetric RT-PCR. Consequently,
relatively shorter probes were used for flavivirus to elim-
inate cross signals among flavivirus species due to the
homology of the genomic sequences of the 3′UTRs. On
the other hand, our method did not distinguish between
B. malayi and B. timori because the target sequences
(i.e. HhaIrepeat sequence) are almost identical. Further-
more, methods based on DNA hybridization inevitably
appeared cross signal with off target capture probes, es-
pecially for the samples containing extremely high con-
centrations of the target pathogens. Consequently, the
cut-off values of capture probes showed in Table 5 need
to be adjusted and refined to test the different concen-
trations of the target pathogen for future application. At
present, there are many commercial extraction kits avail-
able to extract genomic RNA and DNA from diverse
origins, so the proposed strategy can potentially detect
these MBVs and MBPs regardless of the origins of these
pathogens. In the proof-of-concept experiment, we spiked
uninfected mosquito pools with VLPs or plasmids, dem-
onstrated that our CL imaging DNA hybridization method
could detect target MBVs and MBPs in mosquito samples.
Therefore, further research should be focused on extend-
ing the method into the clinical settings for the epidemio-
logical investigations of MBVs and MBPs.
Conclusions
Ultra-sensitive CL imaging DNA hybridization was de-
veloped and could simultaneously detect MBVs and
MBPs. This method is based on horseradish peroxidase
catalyzing luminol-H2O2, and its performance proved to
be rapid, portable, high-throughput, highly sensitive and
specific. The entire operation time, spanning from sam-
ple extraction to result reading, is between 6–8 h. The
method described here has the potential to provide con-
siderable labor savings due to its ability to screen for 19
mosquito-borne pathogens simultaneously.
Additional file
Additional file 1: Figure S1. Determination of the specificity of the
MBVs detection by detection of non-MBVs. A panel of non-MBVs were
detected by this MBVs detection strategy to determine the specificity.
There were no positive results (i.e. detection of these non-MBVs). YFV and
EEEV were used as positive references. (XML 7 kb)
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